

MELODI Strategic Research Agenda Working Group

Meeting Summary – 3 June 2019

The MELODI SRA Working Group met on 3 June 2019 in London, this note provides a brief summary of discussions:

- MELODI workshops:* Review papers from the 2018 workshop on Individual radiosensitivity have been submitted to IJRB and decisions are awaited.

The 2019 Workshop on Non-Cancer Diseases was successfully held in Sitges, Spain 10-12 April 2019. Videos of presentations should be available shortly and four review papers are expected to be drafted for publication.

The 2020 Workshop will be on Inhomogeneous radiation exposures and associated risks. Balázs Madas will be lead organiser and the location is in or close to Budapest Hungary in April 2020.

The proposal for 2021 is Integration of Mechanistic understanding into Risk Assessment. IRSN have offered to organise.

Proposals for future workshops were: Space/cosmic radiation risks (2022, SEK.CEN/GSI), Radiation quality (2023, UniPv), A specific non-cancer disease(s) (2024 or after), a reflection on the achievements of EURATOM funded research over the past 10 years or so.
- MELODI sessions at ERPW2019:* Plans for the ERPW2019 are firming up. The following MELODI sessions have been agreed: (i) Summary of NCD workshop – E. Cardis and J-R Jourdain to organise/chair, (ii) MELODI SRA and 10 years on – what has been achieved and what next? – S Bouffler to chair, panel discussion to follow (iii) What more can be expected from epidemiology and what can radiobiology offer for quantitative risk assessment? – L. Roy and one other to organise/chair
- Joint Platforms roadmap:* B. Madas and G Safrany represented MELODI at a recent workshop dedicated to the joint roadmap held in Brussels. The feasibility/impact approach to prioritisation taken by MELODI was well received. To maintain visibility of MELODI interests in the joint roadmap, the importance of topics for RP policy must be clear.
- SRA revision:* Members are actively working on revision of the SRA that is likely to be restructured around two core issues – (i) the magnitude of cancer risk and (ii) the magnitude of non-cancer disease risk with two cross-cutting issues – (i) the variation in risk between individuals and (ii) the impact of special and temporal aspects of dose delivery on risk. Progress in recent years will be covered in brief and links to key policy issues will be emphasised. The revision will be presented during ERPW2019.